Optimizing Engineered Stealth Features for Allogeneic Cell Therapies
Time: 2:00 pm
day: Day 1 - Track A - PM
Details:
- Comprehensive allo-evasion engineering addressing both cellular and humoral allo-rejection mechanisms:
- HLA knock-out to prevent T-cell rejection
- HLA class I surrogate overexpression and TASR technology to prevent NK cell rejection
- IdeS to degrade pre-existing or de novo generated antibodies directed to the product
- Sharing preclinical and clinical insights of this approach in NHL and autoimmune disease
